Hypoglycaemic effect of catalpol in a mouse model of high-fat diet-induced pre-diabetes

Authors
D Xu, X Huang, HM Hassan, L Wang, S Li, Z Jiang


Lab
China Pharmaceutical University, Jiangsu Key Laboratory of Drug Screening, Nanjing, China

Journal
Applied Physiology, Nutrition, and Metabolism

Abstract
Type 2 diabetes mellitus is a major health problem and a societal burden. Individuals with pre-diabetes are at increased risk of type 2 diabetes mellitus. Catalpol, an iridoid glycoside, has been reported to exert a hypoglycaemic effect in db/db mice, but its effect on the progression of pre-diabetes is unclear. In this study, we established a mouse model of pre-diabetes and examined the hypoglycaemic effect, and the mechanism of any such effect, of catalpol. Catalpol (200 mg/kg/day) had no effect on glucose tolerance or the serum lipid level in a mouse model of impaired glucose tolerance (IGT)-stage pre-diabetes. However, catalpol (200 mg/kg/day) increased insulin sensitivity and decreased the fasting glucose level in a mouse model of impaired fasting glucose/impaired glucose tolerance-stage pre-diabetes. Moreover, catalpol increased the mitochondrial membrane potential (1.52-fold) and ATP content (1.87-fold) in skeletal muscle and improved skeletal muscle function. These effects were mediated by activation of the IRS-1/GLUT4 signalling pathway in skeletal muscle. Our findings will facilitate the development of a novel approach to suppressing the progression of diabetes at an early stage.

BIOSEB Instruments Used:
Grip strength test (BIO-GS3)

Produits associés

DEMANDE DE PUBLICATION

Merci de votre intérêt pour notre gamme de produits et de votre demande pour cette publication qui vous sera envoyée si l'équipe de recherche et la revue le permettent. Notre équipe commerciale vous contactera dans les plus brefs délais.